Gotham Asset Management LLC Grows Stake in Haemonetics Corporation (HAE)
Gotham Asset Management LLC lifted its holdings in Haemonetics Corporation (NYSE:HAE) by 137.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 37,473 shares of the medical instruments supplier’s stock after acquiring an additional 21,665 shares during the quarter. Gotham Asset Management LLC owned 0.07% of Haemonetics Corporation worth $1,480,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in HAE. BlackRock Inc. increased its stake in shares of Haemonetics Corporation by 48,854.9% in the first quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock worth $255,175,000 after acquiring an additional 6,276,880 shares during the period. Vanguard Group Inc. increased its stake in shares of Haemonetics Corporation by 7.6% in the first quarter. Vanguard Group Inc. now owns 4,694,325 shares of the medical instruments supplier’s stock worth $190,449,000 after acquiring an additional 332,087 shares during the period. HealthCor Management L.P. increased its stake in shares of Haemonetics Corporation by 15.9% in the second quarter. HealthCor Management L.P. now owns 1,854,872 shares of the medical instruments supplier’s stock worth $73,249,000 after acquiring an additional 254,872 shares during the period. Wells Fargo & Company MN increased its stake in shares of Haemonetics Corporation by 9.3% in the second quarter. Wells Fargo & Company MN now owns 2,788,122 shares of the medical instruments supplier’s stock worth $110,104,000 after acquiring an additional 238,294 shares during the period. Finally, Anchor Capital Advisors LLC increased its stake in shares of Haemonetics Corporation by 41.7% in the second quarter. Anchor Capital Advisors LLC now owns 774,906 shares of the medical instruments supplier’s stock worth $30,601,000 after acquiring an additional 227,941 shares during the period.
ILLEGAL ACTIVITY WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/gotham-asset-management-llc-grows-stake-in-haemonetics-corporation-hae/1636247.html.
Shares of Haemonetics Corporation (HAE) opened at 45.43 on Tuesday. The company’s 50-day moving average is $43.70 and its 200-day moving average is $41.64. Haemonetics Corporation has a one year low of $32.76 and a one year high of $46.85. The stock has a market capitalization of $2.39 billion, a P/E ratio of 590.00 and a beta of 0.87.
Haemonetics Corporation (NYSE:HAE) last announced its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. The company had revenue of $211.00 million for the quarter, compared to analysts’ expectations of $211.29 million. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. Haemonetics Corporation’s revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.25 EPS. On average, equities research analysts anticipate that Haemonetics Corporation will post $1.61 earnings per share for the current year.
A number of analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th. JMP Securities upgraded shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a research note on Thursday, July 13th. BidaskClub upgraded shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 8th. Jefferies Group LLC reissued a “buy” rating and set a $48.00 price target on shares of Haemonetics Corporation in a report on Thursday, July 27th. Finally, TheStreet raised shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $44.83.
Haemonetics Corporation Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.